The combination of trastuzumab, pertuzumab, and a taxane significantly prolonged progression-free survival (PFS) in a randomized trial5 and is now the standard first-line treatment for HER2-positive breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.